C-1311

C-1311 is a synthetic **imidazoacridinone derivative** developed as an anti-tumor agent. It acts primarily as a DNA-damaging agent through **intercalation/alkylation**, causing DNA strand breaks by inhibiting DNA topoisomerase II, and halting cancer cell proliferation. C-1311 also acts as a **FLT3 (Fms-like tyrosine kinase 3) inhibitor** and mitosis inhibitor, with additional activities such as inhibition of receptor kinases (notably FLT3), cytochrome P450 1A2 and 3A4 isoenzymes, and angiogenesis via the HIF-1α/VEGF pathway. It was investigated in clinical trials for multiple cancers (AML, breast, colorectal, lymphoid), but development has been discontinued. The drug induces p53-dependent senescence in non-cancerous cells and mitotic catastrophe/apoptosis especially in p53-deficient cancer cells. It also has radiosensitizing properties.[1][2][3][4][5]

Brand names

SymadexSymadex Pathfinder

Other names

ImidacrineImidazoloacridine